Podocyte COX-2 exacerbates diabetic nephropathy by increasing podocyte (pro)renin receptor expression

J Am Soc Nephrol. 2011 Jul;22(7):1240-51. doi: 10.1681/ASN.2010111149.

Abstract

Diabetic nephropathy (DN) increases podocyte cyclooxygenase-2 (COX-2) expression, and COX-2 inhibition reduces proteinuria and glomerular injury in animal models of diabetes. To investigate the role of podocyte COX-2 in development of diabetic nephropathy, we employed a streptozotocin model of diabetic mellitus in wild-type and transgenic mice expressing COX-2 selectively in podocytes. Progressive albuminuria developed only in diabetic COX-2 transgenic mice despite hyperglycemia, BP, and GFR being similar to those in wild-type mice. Transgenic mice also manifested significant foot-process effacement, moderate mesangial expansion, and segmental thickening of the glomerular basement membrane. In cultured podocytes overexpressing COX-2, high glucose induced cell injury and increased both expression of the pro(renin) receptor and activation of the renin-angiotensin system. Downregulation of the (pro)renin receptor attenuated the injury induced by high glucose. In vivo, podocyte pro(renin) receptor expression increased in diabetic COX-2-transgenic mice, and treatment with a COX-2 inhibitor abrogated the upregulation of (pro)renin receptor and reduced albuminuria, foot-process effacement, and mesangial matrix expansion. In summary, these results demonstrate that increased expression of podocyte COX-2 predisposes to diabetic glomerular injury and that the (pro)renin receptor may be one mediator for this increased susceptibility to injury.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Cells, Cultured / drug effects
  • Culture Media / pharmacology
  • Cyclooxygenase 2 / metabolism*
  • Cyclooxygenase Inhibitors / therapeutic use
  • Diabetes Mellitus, Experimental / drug therapy
  • Diabetic Nephropathies / metabolism*
  • Diabetic Nephropathies / prevention & control
  • Glucose / pharmacology
  • Male
  • Mice
  • Mice, Transgenic
  • Podocytes / drug effects
  • Podocytes / metabolism*
  • Prorenin Receptor
  • Pyrazoles / therapeutic use
  • Receptors, Cell Surface / metabolism*
  • Sulfonamides / therapeutic use

Substances

  • 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
  • Culture Media
  • Cyclooxygenase Inhibitors
  • Pyrazoles
  • Receptors, Cell Surface
  • Sulfonamides
  • Ptgs2 protein, mouse
  • Cyclooxygenase 2
  • Glucose
  • Prorenin Receptor